Ewing sarcoma family of tumors: A model for the new era of integrated laboratory diagnostics

Expert Review of Molecular Diagnostics

Volumn 8, Issue 1, 2008, Pages 97-105

  Khoury, Joseph D ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

Childhood cancer; Ewing sarcoma; EWS FLI1; Primitive neuroectodermal tumor; t(11; 22)

Indexed keywords

RNA BINDING PROTEIN EWS;

CHROMOSOME TRANSLOCATION; EWING SARCOMA; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; GENE TRANSLOCATION; GENETICS; METABOLISM; POLYMERASE CHAIN REACTION;

HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; POLYMERASE CHAIN REACTION; RNA-BINDING PROTEIN EWS; SARCOMA, EWING'S; TRANSLOCATION, GENETIC;

EID: 38149119736     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.1.97     Document Type: Review

References (87)

1. Ries LAG EM, Kosary CL, Hankey BF et al. SEER Cancer Statistics Review, 1975-2001. National Cancer Institute, Bethesda, MD, USA (2004).
2. Wilkins RM, Pritchard DJ, Burgert EO Jr et al. Ewing's sarcoma of bone. Experience with 140 patients. Cancer 58, 2551-2555 (1986).
3. Cotterill SJ, Ahrens S, Paulussen M et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J. Clin. Oncol. 18, 3108-3114 (2000).
4. Fizazi K, Dohollou N, Blay JY et al. Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J. Clin. Oncol. 16, 3736-3743 (1998).
5. Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J. Bone Joint Surg. Am. 82, 667-674 (2000).
6. Hoffmann C, Ahrens S, Dunst J et al. Pelvic Ewing sarcoma: a retrospective analysis of 241 cases. Cancer 85, 869-877 (1999).
7. O'Sullivan MJ, Perlman EJ, Furman J et al. Visceral primitive peripheral neuroectodermal tumors: a clinicopathologic and molecular study. Hum. Pathol. 32, 1109-1115 (2001).
8. Hasegawa SL, Davison JM, Rutten A et al. Primary cutaneous Ewing's sarcoma: immunophenotypic and molecular cytogenetic evaluation of five cases. Am. J. Surg. Pathol. 22, 310-318 (1998).
9. Jimenez RE, Folpe AL, Lapham RL et al. Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney: a clinicopathologic and immunohistochemical analysis of 11 cases. Am. J. Surg. Pathol. 26, 320-327 (2002).
10. Rodriguez-Galindo C. Pharmacological management of Ewing sarcoma family of tumours. Expert Opin. Pharmacother. 5, 1257-1270 (2004).
11. Paulussen M, Ahrens S, Burdach S et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann. Oncol. 9, 275-281 (1998).
12. Rodriguez-Galindo C, Navid F, Liu T et al. Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann. Oncol. (2007) (In Press).
13. Askin FB, Rosai J, Sibley RK et al. Malignant small cell tumor of the thoracopulmonary region in childhood: a distinctive clinicopathologic entity of uncertain histogenesis. Cancer 43, 2438-2451 (1979).
14. Ewing J. Diffuse endothelioma of bone. Proc. NY Pathol. Soc. 21, 17-24 (1921).
15. Stout AP. A tumor of the ulnar nerve. Proc. NY Pathol. Soc. 12, 2-12 (1918).
16. Delattre O, Zucman J, Melot T et al. The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N. Engl. J. Med. 331, 294-299 (1994).
17. Ushigome U, Machinami R, Sorensen PH. Ewing sarcoma/primitive neuroectodermal tumour (PNET). In: Fletcher CDM, Unni KK, Mertens F (Eds). World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Soft Tissue and Bone. IARC Press, Lyon, France. 298-300 (2002).
18. Turc-Carel C, Philip I, Berger MP et al. [Chromosomal translocation (11; 22) in cell lines of Ewing's sarcoma]. CR Seances Acad. Sci. III 296, 1101-1103 (1983).
19. Delattre O, Zucman J, Plougastel B et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359, 162-165 (1992).
20. May WA, Gishizky ML, Lessnick SL et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc. Natl Acad. Sci. USA 90, 5752-5756 (1993).
21. Sorensen PH, Lessnick SL, Lopez-Terrada D et al. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat. Genet. 6, 146-151 (1994).
22. Jeon IS, Davis JN, Braun BS et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene 10, 1229-1234 (1995).
23. Kaneko Y, Yoshida K, Handa M et al. Fusion of an ETS-family gene, E1AF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy. Genes Chromosomes Cancer 15, 115-121 (1996).
24. Urano F, Umezawa A, Hong W et al. A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma. Biochem. Biophys. Res. Commun. 219, 608-612 (1996).
25. Peter M, Couturier J, Pacquement H et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 14, 1159-1164 (1997).
26. Mastrangelo T, Modena P, Tornielli S et al. A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene 19, 3799-3804 (2000).
27. Plougastel B, Zucman J, Peter M et al. Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation. Genomics 18, 609-615 (1993).
28. Ohno T, Ouchida M, Lee L et al. The EWS gene, involved in Ewing family of tumors, malignant melanoma of soft parts and desmoplastic small round cell tumors, codes for an RNA binding protein with novel regulatory domains. Oncogene 9, 3087-3097 (1994).
29. Bertolotti A, Lutz Y, Heard DJ et al. hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. EMBO J. 15, 5022-5031 (1996).
30. Aman P, Panagopoulos I, Lassen C et al. Expression patterns of the human sarcoma-associated genes FUS and EWS and the genomic structure of FUS. Genomics 37, 1-8 (1996).
31. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat. Rev. Cancer 3, 685-694 (2003).
32. Shing DC, McMullan DJ, Roberts P et al. FUS/ERG gene fusions in Ewing's tumors. Cancer Res. 63, 4568-4576 (2003).
33. Ng TL, O'Sullivan MJ, Pallen CJ et al. Ewing sarcoma with novel translocation t(2;16) producing an in-frame fusion of FUS and FEV. J. Mol. Diagn. 9, 459-463 (2007).
34. Sementchenko VI, Watson DK. Ets target genes: past, present and future. Oncogene 19, 6533-6548 (2000).
35. Sharrocks AD. The ETS-domain transcription factor family. Nat. Rev. Mol. Cell Biol. 2, 827-837 (2001).
36. Folpe AL, Chand EM, Goldblum JR et al. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am. J. Surg. Pathol. 25, 1061-1066 (2001).
37. Truong AH, Ben-David Y. The role of Fli-1 in normal cell function and malignant transformation. Oncogene 19, 6482-6489 (2000).
38. Perlman EJ, Dickman PS, Askin FB et al. Ewing's sarcoma - routine diagnostic utilization of MIC2 analysis: a Pediatric Oncology Group/Children's Cancer Group Intergroup Study. Hum. Pathol. 25, 304-307 (1994).
39. Fellinger EJ, Garin-Chesa P, Triche TJ et al. Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32MIC2. Am. J. Pathol. 139, 317-325 (1991).
40. Kovar H, Dworzak M, Strehl S et al. Overexpression of the pseudoautosomal gene MIC2 in Ewing's sarcoma and peripheral primitive neuroectodermal tumor. Oncogene 5, 1067-1070 (1990).
41. Ambros IM, Ambros PF, Strehl S et al. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 67, 1886-1893 (1991).
42. Banting GS, Pym B, Darling SM et al. The MIC2 gene product: epitope mapping and structural prediction analysis define an integral membrane protein. Mol. Immunol. 26, 181-188 (1989).
43. Darling SM, Goodfellow PJ, Pym B et al. Molecular genetics of MIC2: a gene shared by the human X and Y chromosomes. Cold Spring Harb. Symp. Quant. Biol. 51(Pt 1), 205-212 (1986).
44. Bernard A, Aubrit F, Raynal B et al. A T cell surface molecule different from CD2 is involved in spontaneous rosette formation with erythrocytes. J. Immunol. 140, 1802-1807 (1988).
45. Gelin C, Aubrit F, Phalipon A et al. The E2 antigen, a 32 kd glycoprotein involved in T-cell adhesion processes, is the MIC2 gene product. EMBO J. 8, 3253-3259 (1989).
46. Dworzak MN, Fritsch G, Fleischer C et al. CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis. Br. J. Haematol. 105, 690-695 (1999).
47. Waclavicek M, Majdic O, Stulnig T et al. CD99 engagement on human peripheral blood T cells results in TCR/CD3-dependent cellular activation and allows for Th1-restricted cytokine production. J. Immunol. 161, 4671-4678 (1998).
48. Wingett D, Forcier K, Nielson CP. A role for CD99 in T cell activation. Cell Immunol. 193, 17-23 (1999).
49. Bernard G, Breittmayer JP, de Matteis M et al. Apoptosis of immature thymocytes mediated by E2/CD99. J. Immunol. 158, 2543-2550 (1997).
50. Hahn JH, Kim MK, Choi EY et al. CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J. Immunol. 159, 2250-2258 (1997).
51. + thymocytes. J. Immunol. 154, 26-32 (1995).
52. Cerisano V, Aalto Y, Perdichizzi S et al. Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene 23, 5664-5674 (2004).
53. Schenkel AR, Mamdouh Z, Chen X et al. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat. Immunol. 3, 143-150 (2002).
54. Kreppel M, Aryee DN, Schaefer KL et al. Suppression of KCMF1 by constitutive high CD99 expression is involved in the migratory ability of Ewing's sarcoma cells. Oncogene 25, 2795-2800 (2006).
55. Scotlandi K, Baldini N, Cerisano V et al. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res. 60, 5134-5142 (2000).
56. Scotlandi K, Perdichizzi S, Bernard G et al. Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing's sarcoma. Eur. J. Cancer 42, 91-96 (2006).
57. Lucas DR, Bentley G, Dan ME et al. Ewing sarcoma vs lymphoblastic lymphoma. A comparative immunohistochemical study. Am. J. Clin. Pathol. 115, 11-17 (2001).
58. Fellinger EJ, Garin-Chesa P, Glasser DB et al. Comparison of cell surface antigen HBA71 (p30/32MIC2), neuron-specific enolase, and vimentin in the immunohistochemical analysis of Ewing's sarcoma of bone. Am. J. Surg. Pathol. 16, 746-755 (1992).
59. Scotlandi K, Serra M, Manara MC et al. Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor. Hum. Pathol. 27, 408-416 (1996).
60. Mhawech-Fauceglia P, Herrmann F, Penetrante R et al. Diagnostic utility of FLI-1 monoclonal antibody and dual-colour, break-apart probe fluorescence in situ (FISH) analysis in Ewing's sarcoma/primitive neuroectodermal tumour (EWS/PNET). A comparative study with CD99 and FLI-1 polyclonal antibodies. Histopathology 49, 569-575 (2006).
61. Folpe AL, Hill CE, Parham DM et al. Immunohistochemical detection of FLI-1 protein expression: a study of 132 round cell tumors with emphasis on CD99-positive mimics of Ewing's sarcoma/primitive neuroectodermal tumor. Am. J. Surg. Pathol. 24, 1657-1662 (2000).
62. Amann G, Zoubek A, Salzer-Kuntschik M et al. Relation of neurological marker expression and EWS gene fusion types in MIC2/CD99-positive tumors of the Ewing family. Hum. Pathol. 30, 1058-1064 (1999).
63. Franchi A, Pasquinelli G, Cenacchi G et al. Immunohistochemical and ultrastructural investigation of neural differentiation in Ewing sarcoma/PNET of bone and soft tissues. Ultrastruct. Pathol. 25, 219-225 (2001).
64. Zucman J, Melot T, Desmaze C et al. Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J. 12, 4481-4487 (1993).
65. Zucman J, Delattre O, Desmaze C et al. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer 5, 271-277 (1992).
66. Zoubek A, Pfleiderer C, Salzer-Kuntschik M et al. Variability of EWS chimaeric transcripts in Ewing tumours: a comparison of clinical and molecular data. Br. J. Cancer 70, 908-913 (1994).
67. Zoubek A, Dockhorn-Dworniczak B, Delattre O et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J. Clin. Oncol. 14, 1245-1251 (1996).
68. Meier VS, Kuhne T, Jundt G et al. Molecular diagnosis of Ewing tumors: improved detection of EWS-FLI-1 and EWS-ERG chimeric transcripts and rapid determination of exon combinations. Diagn. Mol. Pathol. 7, 29-35 (1998).
69. Peter M, Gilbert E, Delattre O. A multiplex real-time pcr assay for the detection of gene fusions observed in solid tumors. Lab. Invest. 81, 905-912 (2001).
70. Adams V, Hany MA, Schmid M et al. Detection of t(11;22)(q24;q12) translocation breakpoint in paraffin-embedded tissue of the Ewing's sarcoma family by nested reverse transcription-polymerase chain reaction. Diagn. Mol. Pathol. 5, 107-113 (1996).
71. Hisaoka M, Tsuji S, Morimitsu Y et al. Molecular detection of EWS-FLI1 chimeric transcripts in Ewing family tumors by nested reverse transcription-polymerase chain reaction: application to archival paraffin-embedded tumor tissues. Apmis 107, 577-584 (1999).
72. Fritsch MK, Bridge JA, Schuster AE et al. Performance characteristics of a reverse transcriptase-polymerase chain reaction assay for the detection of tumor-specific fusion transcripts from archival tissue. Pediatr. Dev. Pathol. 6, 43-53 (2003).
73. Lewis TB, Coffin CM, Bernard PS. Differentiating Ewing's sarcoma from other round blue cell tumors using a RT-PCR translocation panel on formalin-fixed paraffin-embedded tissues. Mod. Pathol. 20, 397-404 (2007).
74. Stegmaier S, Leuschner I, Aakcha-Rudel E et al. Identification of various exon combinations of the ews/fli1 translocation: an optimized RT-PCR method for paraffin embedded tissue - a report by the CWS-study group. Klin. Padiatr. 216, 315-322 (2004).
75. Fagnou C, Michon J, Peter M et al. Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor. Societe Francaise d'Oncologie Pediatrique. J. Clin. Oncol. 16, 1707-1711 (1998).
76. Zoubek A, Ladenstein R, Windhager R et al. Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: a preliminary evaluation. Int. J. Cancer 79, 56-60 (1998).
77. West DC, Grier HE, Swallow MM et al. Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor. J. Clin. Oncol. 15, 583-588 (1997).
78. Schleiermacher G, Peter M, Oberlin O et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized ewing tumor. J. Clin. Oncol. 21, 85-91 (2003).
79. Lin PP, Brody RI, Hamelin AC et al. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Cancer Res. 59, 1428-1432 (1999).
80. de Alava E, Kawai A, Healey JH et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J. Clin. Oncol. 16, 1248-1255 (1998).
81. Ginsberg JP, de Alava E, Ladanyi M et al. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J. Clin. Oncol. 17, 1809-1814 (1999).
82. Bridge RS, Rajaram V, Dehner LP et al. Molecular diagnosis of Ewing sarcoma/primitive neuroectodermal tumor in routinely processed tissue: a comparison of two FISH strategies and RT-PCR in malignant round cell tumors. Mod. Pathol. 19, 1-8 (2006).
83. Qian X, Jin L, Shearer BM et al. Molecular diagnosis of Ewing's sarcoma/primitive neuroectodermal tumor in formalin-fixed paraffin-embedded tissues by RT-PCR and fluorescence in situ hybridization. Diagn. Mol. Pathol. 14, 23-28 (2005).
84. Nagao K, Ito H, Yoshida H et al. Chromosomal rearrangement t(11;22) in extraskeletal Ewing's sarcoma and primitive neuroectodermal tumour analysed by fluorescence in situ hybridization using paraffin-embedded tissue. J. Pathol. 181, 62-66 (1997).
85. Taylor C, Patel K, Jones T et al. Diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumour based on the detection of t(11;22) using fluorescence in situ hybridisation. Br. J. Cancer 67, 128-133 (1993).
86. Kumar S, Pack S, Kumar D et al. Detection of EWS-FLI-1 fusion in Ewing's sarcoma/peripheral primitive neuroectodermal tumor by fluorescence in situ hybridization using formalin-fixed paraffin-embedded tissue. Hum. Pathol. 30, 324-330 (1999).
87. Fuller CE, Dalton J, Jenkins JJ et al. Detection of translocations involving the EWS gene locus in Ewing sarcoma/primitive neuroectodermal tumor and desmoplastic small round cell tumor by dual color break-apart probe FISH assay. Mod. Pathol. 17, 329a (2004).